Literature DB >> 7593605

Distinct roles for B7-1 (CD-80) and B7-2 (CD-86) in the initiation of experimental allergic encephalomyelitis.

M K Racke1, D E Scott, L Quigley, G S Gray, R Abe, C H June, P J Perrin.   

Abstract

The activation and differentiation of T cells require both antigen/MHC recognition and costimulatory signals. The present studies examined the role of B7-1 (CD80) and B7-2 (CD86) costimulation in the prototypic autoimmune disorder, experimental allergic encephalomyelitis (EAE). In adoptively transferred EAE, in vitro activation of myelin basic protein (MBP)-specific lymph node cells was inhibited by the combination of anti-CD80 plus anti-CD86, but not individually. However, in actively induced disease, one injection of anti-CD80 significantly reduced disease, while anti-CD86 exacerbated disease. Interestingly, one injection of CTLA-4Ig suppressed disease, while multiple injections resulted in enhanced disease. Thus, the costimulation provided by B7-1 molecules appears to be important for the development of encephalitogenic T cells. The enhanced disease caused by multiple injections of CTLA-4Ig or a single injection of anti-CD86 suggests an inhibitory function for CD86 interaction with its counterreceptors CD28 and CTLA-4 in EAE. Alternatively, these results are consistent with an essential timing requirement for the coordinated interaction of B7 and CD28 family receptors, and that disruption of this critical timing can have opposing results on the outcome of an immune response.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7593605      PMCID: PMC185869          DOI: 10.1172/JCI118274

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  57 in total

1.  Identification of an alternatively spliced form of the murine homologue of B7.

Authors:  M Inobe; P S Linsley; J A Ledbetter; Y Nagai; M Tamakoshi; T Uede
Journal:  Biochem Biophys Res Commun       Date:  1994-04-15       Impact factor: 3.575

2.  Activated human B lymphocytes express three CTLA-4 counterreceptors that costimulate T-cell activation.

Authors:  V A Boussiotis; G J Freeman; J G Gribben; J Daley; G Gray; L M Nadler
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-01       Impact factor: 11.205

3.  Expression and functional significance of an additional ligand for CTLA-4.

Authors:  D J Lenschow; G H Su; L A Zuckerman; N Nabavi; C L Jellis; G S Gray; J Miller; J A Bluestone
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-01       Impact factor: 11.205

4.  Differentiation of encephalitogenic T cells confers resistance to an inhibitory anti-CD4 monoclonal antibody.

Authors:  M D Mannie; J Morrison-Plummer; T J McConnell
Journal:  J Immunol       Date:  1993-12-15       Impact factor: 5.422

5.  Evidence for an additional ligand, distinct from B7, for the CTLA-4 receptor.

Authors:  Z Razi-Wolf; F Galvin; G Gray; H Reiser
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-01       Impact factor: 11.205

6.  Naive versus memory CD4 T cell response to antigen. Memory cells are less dependent on accessory cell costimulation and can respond to many antigen-presenting cell types including resting B cells.

Authors:  M Croft; L M Bradley; S L Swain
Journal:  J Immunol       Date:  1994-03-15       Impact factor: 5.422

7.  Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production.

Authors:  G J Freeman; F Borriello; R J Hodes; H Reiser; J G Gribben; J W Ng; J Kim; J M Goldberg; K Hathcock; G Laszlo
Journal:  J Exp Med       Date:  1993-12-01       Impact factor: 14.307

8.  CD28-mediated costimulation of interleukin 2 (IL-2) production plays a critical role in T cell priming for IL-4 and interferon gamma production.

Authors:  R A Seder; R N Germain; P S Linsley; W E Paul
Journal:  J Exp Med       Date:  1994-01-01       Impact factor: 14.307

9.  CD4pos, NK1.1pos T cells promptly produce interleukin 4 in response to in vivo challenge with anti-CD3.

Authors:  T Yoshimoto; W E Paul
Journal:  J Exp Med       Date:  1994-04-01       Impact factor: 14.307

10.  Mice transgenic for a soluble form of murine CTLA-4 show enhanced expansion of antigen-specific CD4+ T cells and defective antibody production in vivo.

Authors:  F Ronchese; B Hausmann; S Hubele; P Lane
Journal:  J Exp Med       Date:  1994-03-01       Impact factor: 14.307

View more
  46 in total

1.  CD28-independent induction of experimental autoimmune encephalomyelitis.

Authors:  T Chitnis; N Najafian; K A Abdallah; V Dong; H Yagita; M H Sayegh; S J Khoury
Journal:  J Clin Invest       Date:  2001-03       Impact factor: 14.808

2.  CD28 costimulatory blockade exacerbates disease severity and accelerates epitope spreading in a virus-induced autoimmune disease.

Authors:  K L Neville; M C Dal Canto; J A Bluestone; S D Miller
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

Review 3.  Regulation and function of class II major histocompatibility complex, CD40, and B7 expression in macrophages and microglia: Implications in neurological diseases.

Authors:  George M O'Keefe; Vince T Nguyen; Etty N Benveniste
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

Review 4.  Immune checkpoints in central nervous system autoimmunity.

Authors:  Nicole Joller; Anneli Peters; Ana C Anderson; Vijay K Kuchroo
Journal:  Immunol Rev       Date:  2012-07       Impact factor: 12.988

5.  Cutting edge: The transcription factor Kruppel-like factor 4 regulates the differentiation of Th17 cells independently of RORγt.

Authors:  Lori Lebson; Anne Gocke; Jason Rosenzweig; Jonathan Alder; Curt Civin; Peter A Calabresi; Katharine A Whartenby
Journal:  J Immunol       Date:  2010-11-12       Impact factor: 5.422

6.  Treatment with anti-CD86 costimulatory molecule prevents the autoimmune lesions in murine Sjögren's syndrome (SS) through up-regulated Th2 response.

Authors:  K Saegusa; N Ishimaru; K Yanagi; N Haneji; M Nishino; M Azuma; I Saito; Y Hayashi
Journal:  Clin Exp Immunol       Date:  2000-02       Impact factor: 4.330

Review 7.  The balance of immune responses: costimulation verse coinhibition.

Authors:  Sumit K Subudhi; Maria-Luisa Alegre; Yang-Xin Fu
Journal:  J Mol Med (Berl)       Date:  2005-01-04       Impact factor: 4.599

Review 8.  Targeting the B7 family of co-stimulatory molecules: successes and challenges.

Authors:  Joseph R Podojil; Stephen D Miller
Journal:  BioDrugs       Date:  2013-02       Impact factor: 5.807

9.  Intracellular expression of Mycobacterium tuberculosis-specific 10-kDa antigen down-regulates macrophage B7.1 expression and nitric oxide release.

Authors:  B Singh; G Singh; V Trajkovic; P Sharma
Journal:  Clin Exp Immunol       Date:  2003-10       Impact factor: 4.330

Review 10.  Co-stimulatory and Co-inhibitory Pathways in Autoimmunity.

Authors:  Qianxia Zhang; Dario A A Vignali
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.